Log In Get Started
Press Releases April 14, 2026 04:15 PM

NL INDUSTRIES ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE

NL Industries announces scheduled release date for Q1 2026 earnings report

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
NL

NL Industries, Inc., a company involved in component products and chemical production, plans to release its first quarter 2026 earnings report after market close on May 6, 2026, pending completion of quarter-end closing procedures.

NL INDUSTRIES ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE
NL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release scheduled for May 6, 2026, after market close.
  • Company operates in component products including security products and recreational marine components, as well as chemicals, specifically TiO2.
  • The announcement is a routine update on earnings release timing.

Dallas, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- NL Industries, Inc. (NYSE: NL) today announced that, subject to the completion of quarter-end closing procedures, it expects to report first quarter 2026 earnings in a press release after market close on Wednesday, May 6, 2026. 

NL Industries, Inc. is engaged in the component products (security products and recreational marine components) and chemicals (TiO2) businesses.

* * * * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700


Risks

  • Uncertainty in quarter-end closing procedures could delay the earnings release.
  • Potential volatility in chemical and component product markets affecting financial results.
  • Economic factors influencing demand in security products, marine components, and TiO2 sectors.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026